ZIMLAB137.20

Zim Laboratories Limited

· Pharma & Health
₹ CrorePeersANUHPHRVALIANTLABAHCLALBERTDAVDWANBURYHALEOSLABSBAJAJHCARETHEMISMEDMcap ₹734 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity7.224.821.971.97
Return on Assets3.862.581.081.08
Return on Capital Employed8.837.732.872.87
Return on Invested Capital5.524.401.811.43
Margins
EBITDA Margin11.2511.548.027.11
Operating Margin6.916.232.682.68
Incremental Operating Margin-15.24293.28
Pretax Margin6.434.752.191.28
Net Income Margin4.693.211.560.93
Net Income to Common Margin4.693.211.560.93
FCF Margin-15.690.091.371.37
Additional
Effective Tax Rate27.0532.4528.9127.13
Sustainable Growth Rate7.224.821.971.97
Incremental Operating Margin %-15.24293.28-10.33
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.